NDAORALTABLET
Approved
Jul 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
DIOVAN (valsartan) by Novartis is angiotensin 2 receptor antagonists [moa]. First approved in 2001.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DIOVAN (valsartan) is an oral angiotensin II receptor antagonist (ARB) tablet approved by the FDA in July 2001 for the treatment of hypertension. It works by blocking angiotensin II receptors, preventing vasoconstriction and reducing blood pressure. As a foundational ARB monotherapy, DIOVAN remains a standard-of-care option in hypertension management, though it now competes with combination formulations and newer mechanisms.
$0.0BPart D
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Angiotensin 2 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Sacubitril-valsartan in Patients With Heart Failure With Reduced Ejection Fraction From Rural Tanzania
Started Jun 2026
298 enrolled
Heart Failure
A Real-world Study of Clinical Treatment Guidelines for Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan
Started Jan 2026
500 enrolled
Heart Failure With Reduced Ejection Fraction
Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets
Started May 2024
48 enrolled
Healthy Volunteer
Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets
Started May 2024
40 enrolled
Healthy Subjects
A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Started Jan 2024
48 enrolled
Healthy Volunteers
Worked on DIOVAN at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.